PMID- 33803218
OWN - NLM
STAT- MEDLINE
DCOM- 20211022
LR  - 20211022
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 10
IP  - 3
DP  - 2021 Mar 9
TI  - The Role of IL-9 Polymorphisms and Serum IL-9 Levels in Carcinogenesis and 
      Survival Rate for Laryngeal Squamous Cell Carcinoma.
LID - 10.3390/cells10030601 [doi]
LID - 601
AB  - Recent studies have described the dichotomous function of IL-9 in various cancer 
      diseases. However, its function has still not been analysed in laryngeal squamous 
      cell carcinoma (LSCC). In the present study, we evaluated five single nucleotide 
      polymorphisms (SNPs) of IL-9 (rs1859430, rs2069870, rs11741137, rs2069885, and 
      rs2069884) and determined their associations with the patients' five-year 
      survival rate. Additionally, we analysed serum IL-9 levels using an enzyme-linked 
      immunosorbent assay. Three hundred LSCC patients and 533 control subjects were 
      included in this study. A significant association between the patients' survival 
      rate and distribution of IL-9 rs1859430 variants was revealed: patients carrying 
      AA genotype had a higher risk of dying (p = 0.005). Haplotypes A-G-C-G-G of IL-9 
      (rs1859430, rs2069870, rs11741137, rs2069885, and rs2069884) were associated with 
      47% lower odds of LSCC occurrence (p = 0.035). Serum IL-9 levels were found 
      detectable in three control group subjects (8.99 +/- 12.03 pg/mL). In summary, 
      these findings indicate that the genotypic distribution of IL-9 rs1859430 
      negatively influences the five-year survival rate of LSCC patients. The 
      haplotypes A-G-C-G-G of IL-9 (rs1859430, rs2069870, rs11741137, rs2069885, and 
      rs2069884) are associated with the lower odds of LSCC development.
FAU - Pasvenskaite, Agne
AU  - Pasvenskaite A
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences 
      (LUHS), LT-50161 Kaunas, Lithuania.
FAU - Liutkeviciene, Rasa
AU  - Liutkeviciene R
AD  - Neuroscience Institute, Lithuanian University of Health Sciences (LUHS), LT-50161 
      Kaunas, Lithuania.
FAU - Gedvilaite, Greta
AU  - Gedvilaite G
AD  - Neuroscience Institute, Lithuanian University of Health Sciences (LUHS), LT-50161 
      Kaunas, Lithuania.
FAU - Vilkeviciute, Alvita
AU  - Vilkeviciute A
AUID- ORCID: 0000-0002-0427-5568
AD  - Neuroscience Institute, Lithuanian University of Health Sciences (LUHS), LT-50161 
      Kaunas, Lithuania.
FAU - Liutkevicius, Vykintas
AU  - Liutkevicius V
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences 
      (LUHS), LT-50161 Kaunas, Lithuania.
FAU - Uloza, Virgilijus
AU  - Uloza V
AD  - Department of Otorhinolaryngology, Lithuanian University of Health Sciences 
      (LUHS), LT-50161 Kaunas, Lithuania.
LA  - eng
PT  - Journal Article
DEP - 20210309
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
RN  - 0 (Interleukin-9)
SB  - IM
MH  - Carcinoma, Squamous Cell/blood/*genetics/*mortality
MH  - Case-Control Studies
MH  - Female
MH  - Gene Frequency/genetics
MH  - *Genetic Predisposition to Disease
MH  - Haplotypes/genetics
MH  - Humans
MH  - Interleukin-9/*blood/*genetics
MH  - Laryngeal Neoplasms/*blood/*genetics
MH  - Linkage Disequilibrium/genetics
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Proportional Hazards Models
MH  - Survival Rate
PMC - PMC8001846
OTO - NOTNLM
OT  - IL-9
OT  - laryngeal squamous cell carcinoma
OT  - rs11741137
OT  - rs1859430
OT  - rs2069870
OT  - rs2069884
OT  - rs2069885
OT  - serum levels
OT  - survival rate
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript, or in the decision to publish the results.
EDAT- 2021/04/04 06:00
MHDA- 2023/02/25 06:00
PMCR- 2021/03/09
CRDT- 2021/04/03 01:13
PHST- 2021/02/08 00:00 [received]
PHST- 2021/03/02 00:00 [revised]
PHST- 2021/03/05 00:00 [accepted]
PHST- 2021/04/03 01:13 [entrez]
PHST- 2021/04/04 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2021/03/09 00:00 [pmc-release]
AID - cells10030601 [pii]
AID - cells-10-00601 [pii]
AID - 10.3390/cells10030601 [doi]
PST - epublish
SO  - Cells. 2021 Mar 9;10(3):601. doi: 10.3390/cells10030601.